BNP Paribas Financial Markets Has $6.63 Million Stock Position in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

BNP Paribas Financial Markets grew its stake in shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) by 208.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 149,419 shares of the company’s stock after acquiring an additional 101,000 shares during the period. BNP Paribas Financial Markets’ holdings in SPDR S&P Pharmaceuticals ETF were worth $6,628,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. CX Institutional increased its position in SPDR S&P Pharmaceuticals ETF by 117.2% during the second quarter. CX Institutional now owns 9,711 shares of the company’s stock worth $386,000 after acquiring an additional 5,240 shares during the period. U.S. Capital Wealth Advisors LLC boosted its stake in shares of SPDR S&P Pharmaceuticals ETF by 44.1% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 18,066 shares of the company’s stock valued at $719,000 after buying an additional 5,531 shares during the period. Envestnet Portfolio Solutions Inc. grew its position in SPDR S&P Pharmaceuticals ETF by 2.6% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 58,533 shares of the company’s stock worth $2,328,000 after buying an additional 1,510 shares in the last quarter. AlphaMark Advisors LLC bought a new position in SPDR S&P Pharmaceuticals ETF during the 2nd quarter worth $234,000. Finally, First Citizens Bank & Trust Co. raised its holdings in SPDR S&P Pharmaceuticals ETF by 2.7% in the 2nd quarter. First Citizens Bank & Trust Co. now owns 65,826 shares of the company’s stock valued at $2,619,000 after acquiring an additional 1,709 shares in the last quarter.

SPDR S&P Pharmaceuticals ETF Stock Performance

XPH opened at $46.27 on Tuesday. SPDR S&P Pharmaceuticals ETF has a 52-week low of $37.47 and a 52-week high of $48.76. The firm has a market cap of $224.41 million, a P/E ratio of 14.39 and a beta of 0.87. The business’s fifty day moving average is $45.77 and its 200-day moving average is $43.27.

About SPDR S&P Pharmaceuticals ETF

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.